Analyst Price Target is $6.50
▲ +247.59% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Bionano Genomics in the last 3 months. The average price target is $6.50, with a high forecast of $12.00 and a low forecast of $3.50. The average price target represents a 247.59% upside from the last price of $1.87.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in Bionano Genomics. This Buy consensus rating has held steady for over two years.
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
Read More